D-2570
- Generic Name
- D-2570
Yifang Biopharma's TYK2 Inhibitor D-2570 Shows Promising Phase II Results in Psoriasis Treatment
• Yifang Biopharma's TYK2 inhibitor, D-2570, demonstrated significant efficacy in a Phase II trial for moderate to severe plaque psoriasis, with high PASI 75 response rates across multiple dose groups.
• The Phase II trial of D-2570 met its primary endpoint, showing statistically significant improvements in psoriasis symptoms compared to placebo, with a favorable safety profile.
• Gesolexab (D-1553), a KRAS G12C inhibitor developed by Yifang Biopharma, has completed first subject enrollment in Phase III clinical study for non-small cell lung cancer.
• D-0502, an oral selective estrogen receptor degrader (SERD), is currently in Phase III clinical trials for second-line treatment of ER-positive, HER2-negative breast cancer, showing promising clinical benefit.
InventisBio's D-2570 Shows Promise in Phase 2 Psoriasis Trial
• InventisBio's D-2570, an oral TYK2 inhibitor, demonstrated significant efficacy in treating moderate to severe plaque psoriasis in a Phase 2 trial.
• The study showed that a high percentage of patients achieved PASI 75, PASI 90, and PASI 100 responses with D-2570 compared to placebo at week 12.
• D-2570 exhibited a favorable safety profile, with most adverse events being mild to moderate and no new safety signals identified.
• These results suggest D-2570 could offer a convenient and effective oral alternative to biologics for psoriasis treatment.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath